I don't think this one has been submitted yet. From the March 2007 European Journal of Neurology.


Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

* C. CollinaaDepartment of Neurorehabilitation, Royal Berkshire and Battle NHS Trust, Reading, UK,
* P. DaviesbbDepartment of Neurology, Northampton General Hospital, Northampton, UK,
* I. K. MutibokoccTrial-Link Ltd, Bexhill-on-Sea, UK,
* S. RatcliffeddBarts Pain Research Group, Barts and The London NHS Trust, London, UK
* for ...

Money seems to be what they need right now to move on with their clinical trial program, so this is good news I think.



GW Pharma signs partner for cannabis drug in U.S.

Feb 14 -- Reuters -- GW Pharmaceuticals has signed up Japan's Otsuka Pharmaceuticals Co. to develop and market pioneering cannabis-based drug Sativex in the United States, the UK company said on Wednesday, boosting its shares.

GW, which has a dispensation from the ...

Sativex phase III neuropathic pain trials show benefits: GW Pharma
GW Pharmaceuticals plc announces preliminary results of two phase III studies of Sativex, its cannabinoid spray medicine, in peripheral neuropathic pain.

These studies are part of a programme to generate data for the future expansion of the use of Sativex in Europe beyond Multiple Sclerosis (MS) into other pain conditions.

The results of the study in patients with neuropathic pain characterised by allodynia show ...

Cannabinoid-Based drug Savitex Appears Helpful for Spasticity in Multiple Sclerosis: Presented at ECTRIMS
By Bruce Sylvester

MADRID, SPAIN -- October 3, 2006 -- Patients with progressive multiple sclerosis showed statistically significant improvement in spasticity-related symptoms following treatment with the cannabinoid-based drug Savitex, researchers reported here at the 22nd Congress of the European Committee for Treatment and research in Multiple Sclerosis (ECTRIMS).

"Since the subjects were able to self titrate the drug, they chose their own ...